nodes	percent_of_prediction	percent_of_DWPC	metapath
Ofloxacin—TOP2A—Valrubicin—urinary bladder cancer	0.401	0.535	CbGbCtD
Ofloxacin—TOP2A—Epirubicin—urinary bladder cancer	0.0608	0.081	CbGbCtD
Ofloxacin—TOP2A—Etoposide—urinary bladder cancer	0.0473	0.0631	CbGbCtD
Ofloxacin—ABCC1—Epirubicin—urinary bladder cancer	0.0337	0.0449	CbGbCtD
Ofloxacin—TOP2A—Doxorubicin—urinary bladder cancer	0.0323	0.043	CbGbCtD
Ofloxacin—ABCC1—Etoposide—urinary bladder cancer	0.0262	0.035	CbGbCtD
Ofloxacin—ABCC2—Carboplatin—urinary bladder cancer	0.0231	0.0308	CbGbCtD
Ofloxacin—ABCC2—Cisplatin—urinary bladder cancer	0.0198	0.0263	CbGbCtD
Ofloxacin—ABCC2—Etoposide—urinary bladder cancer	0.0194	0.0259	CbGbCtD
Ofloxacin—ABCC1—Doxorubicin—urinary bladder cancer	0.0179	0.0239	CbGbCtD
Ofloxacin—ABCC1—Methotrexate—urinary bladder cancer	0.0173	0.0231	CbGbCtD
Ofloxacin—ABCC2—Doxorubicin—urinary bladder cancer	0.0132	0.0177	CbGbCtD
Ofloxacin—ABCC2—Methotrexate—urinary bladder cancer	0.0128	0.0171	CbGbCtD
Ofloxacin—SLC22A6—Methotrexate—urinary bladder cancer	0.00939	0.0125	CbGbCtD
Ofloxacin—CYP1A2—Fluorouracil—urinary bladder cancer	0.00867	0.0116	CbGbCtD
Ofloxacin—CYP1A2—Etoposide—urinary bladder cancer	0.00724	0.00965	CbGbCtD
Ofloxacin—CYP1A2—urine—urinary bladder cancer	0.00232	0.105	CbGeAlD
Ofloxacin—TOP2A—prostate gland—urinary bladder cancer	0.00174	0.0785	CbGeAlD
Ofloxacin—SLC22A4—prostate gland—urinary bladder cancer	0.00139	0.0628	CbGeAlD
Ofloxacin—ABCC2—prostate gland—urinary bladder cancer	0.00119	0.0536	CbGeAlD
Ofloxacin—SLC22A4—seminal vesicle—urinary bladder cancer	0.00118	0.0531	CbGeAlD
Ofloxacin—ABCC1—prostate gland—urinary bladder cancer	0.00105	0.0472	CbGeAlD
Ofloxacin—SLC22A4—renal system—urinary bladder cancer	0.000947	0.0428	CbGeAlD
Ofloxacin—SLC22A5—prostate gland—urinary bladder cancer	0.00092	0.0416	CbGeAlD
Ofloxacin—ABCC1—seminal vesicle—urinary bladder cancer	0.000885	0.04	CbGeAlD
Ofloxacin—TOP2A—vagina—urinary bladder cancer	0.000857	0.0387	CbGeAlD
Ofloxacin—ABCC2—renal system—urinary bladder cancer	0.000809	0.0366	CbGeAlD
Ofloxacin—SLC22A5—seminal vesicle—urinary bladder cancer	0.000778	0.0351	CbGeAlD
Ofloxacin—SLC22A4—female reproductive system—urinary bladder cancer	0.000759	0.0343	CbGeAlD
Ofloxacin—ABCC1—urethra—urinary bladder cancer	0.0007	0.0316	CbGeAlD
Ofloxacin—SLC22A4—vagina—urinary bladder cancer	0.000686	0.031	CbGeAlD
Ofloxacin—ABCC2—female reproductive system—urinary bladder cancer	0.000648	0.0293	CbGeAlD
Ofloxacin—SLC22A5—renal system—urinary bladder cancer	0.000627	0.0283	CbGeAlD
Ofloxacin—SLC22A5—urethra—urinary bladder cancer	0.000616	0.0278	CbGeAlD
Ofloxacin—CYP1A2—renal system—urinary bladder cancer	0.000568	0.0257	CbGeAlD
Ofloxacin—TOP2A—lymph node—urinary bladder cancer	0.000555	0.0251	CbGeAlD
Ofloxacin—ABCC1—vagina—urinary bladder cancer	0.000516	0.0233	CbGeAlD
Ofloxacin—SLC22A5—female reproductive system—urinary bladder cancer	0.000502	0.0227	CbGeAlD
Ofloxacin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000484	0.125	CbGdCrCtD
Ofloxacin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000484	0.125	CbGdCrCtD
Ofloxacin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000484	0.125	CbGdCrCtD
Ofloxacin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000484	0.125	CbGdCrCtD
Ofloxacin—SLC22A5—vagina—urinary bladder cancer	0.000454	0.0205	CbGeAlD
Ofloxacin—SLC22A4—lymph node—urinary bladder cancer	0.000444	0.0201	CbGeAlD
Ofloxacin—ABCC2—lymph node—urinary bladder cancer	0.000379	0.0171	CbGeAlD
Ofloxacin—ABCC1—lymph node—urinary bladder cancer	0.000334	0.0151	CbGeAlD
Ofloxacin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000323	0.0835	CbGdCrCtD
Ofloxacin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000323	0.0835	CbGdCrCtD
Ofloxacin—SLC22A5—lymph node—urinary bladder cancer	0.000294	0.0133	CbGeAlD
Ofloxacin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	0.000201	0.00481	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000194	0.00464	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000192	0.0046	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00019	0.00455	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000189	0.00452	CbGpPWpGaD
Ofloxacin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000182	0.047	CbGdCrCtD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000173	0.00416	CbGpPWpGaD
Ofloxacin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000168	0.0436	CbGdCrCtD
Ofloxacin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000168	0.0436	CbGdCrCtD
Ofloxacin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000168	0.0436	CbGdCrCtD
Ofloxacin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	0.000168	0.00404	CbGpPWpGaD
Ofloxacin—SLC22A5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000165	0.00395	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	0.000159	0.00382	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	0.000159	0.00381	CbGpPWpGaD
Ofloxacin—SLC22A4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000158	0.0038	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	0.000157	0.00375	CbGpPWpGaD
Ofloxacin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000156	0.0403	CbGdCrCtD
Ofloxacin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000156	0.0403	CbGdCrCtD
Ofloxacin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000156	0.0403	CbGdCrCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000156	0.00373	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000152	0.00364	CbGpPWpGaD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	0.000151	0.00362	CbGpPWpGaD
Ofloxacin—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000146	0.00349	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	0.000142	0.00341	CbGpPWpGaD
Ofloxacin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000134	0.00322	CbGpPWpGaD
Ofloxacin—ABCC1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000134	0.0032	CbGpPWpGaD
Ofloxacin—ABCC2—NRF2 pathway—NQO1—urinary bladder cancer	0.000133	0.00318	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000131	0.00313	CbGpPWpGaD
Ofloxacin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	0.00013	0.0337	CbGdCrCtD
Ofloxacin—SLC22A4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000129	0.0031	CbGpPWpGaD
Ofloxacin—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000129	0.00309	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000126	0.00301	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000126	0.00301	CbGpPWpGaD
Ofloxacin—SLC22A6—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000124	0.00298	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000124	0.00297	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000124	0.00297	CbGpPWpGaD
Ofloxacin—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000122	0.00293	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.000122	0.00293	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000121	0.00289	CbGpPWpGaD
Ofloxacin—ABCC2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00012	0.00289	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.00012	0.00289	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.00012	0.00289	CbGpPWpGaD
Ofloxacin—SLC22A5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000119	0.00286	CbGpPWpGaD
Ofloxacin—ABCC1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000119	0.00285	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000119	0.00284	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000116	0.00278	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000114	0.00273	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000113	0.00271	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000113	0.0027	CbGpPWpGaD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000112	0.00268	CbGpPWpGaD
Ofloxacin—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000112	0.00268	CbGpPWpGaD
Ofloxacin—ABCC2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000111	0.00265	CbGpPWpGaD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.000108	0.0026	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	0.000108	0.00258	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	0.000108	0.00258	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000106	0.00254	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000105	0.00252	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000103	0.00247	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000102	0.00244	CbGpPWpGaD
Ofloxacin—ABCC2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000102	0.00244	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000101	0.00242	CbGpPWpGaD
Ofloxacin—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000101	0.00241	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	9.92e-05	0.00238	CbGpPWpGaD
Ofloxacin—SLC22A5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.71e-05	0.00233	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	9.33e-05	0.00224	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.28e-05	0.00223	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	9.27e-05	0.00222	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	9.25e-05	0.00222	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	9.21e-05	0.00221	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	8.99e-05	0.00216	CbGpPWpGaD
Ofloxacin—SLC22A6—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.99e-05	0.00215	CbGpPWpGaD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	8.98e-05	0.00215	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	8.88e-05	0.00213	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	8.87e-05	0.00213	CbGpPWpGaD
Ofloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.78e-05	0.00211	CbGpPWpGaD
Ofloxacin—SLC22A4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.72e-05	0.00209	CbGpPWpGaD
Ofloxacin—ABCC2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.71e-05	0.00209	CbGpPWpGaD
Ofloxacin—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	8.62e-05	0.00207	CbGpPWpGaD
Ofloxacin—ABCC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.61e-05	0.00206	CbGpPWpGaD
Ofloxacin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	8.58e-05	0.00206	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	8.43e-05	0.00202	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	8.07e-05	0.00193	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	8.06e-05	0.00193	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.97e-05	0.00191	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	7.88e-05	0.00189	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	7.62e-05	0.00183	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	7.56e-05	0.00181	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	7.54e-05	0.00181	CbGpPWpGaD
Ofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	7.38e-05	0.00177	CbGpPWpGaD
Ofloxacin—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.33e-05	0.00176	CbGpPWpGaD
Ofloxacin—ABCC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.1e-05	0.0017	CbGpPWpGaD
Ofloxacin—ABCC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.02e-05	0.00168	CbGpPWpGaD
Ofloxacin—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	6.78e-05	0.00163	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.76e-05	0.00162	CbGpPWpGaD
Ofloxacin—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	6.69e-05	0.0016	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—GSTO2—urinary bladder cancer	6.66e-05	0.0016	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.61e-05	0.00158	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	6.6e-05	0.00158	CbGpPWpGaD
Ofloxacin—SLC22A5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.56e-05	0.00157	CbGpPWpGaD
Ofloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	6.32e-05	0.00152	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	6.23e-05	0.00149	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.97e-05	0.00143	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	5.88e-05	0.00141	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	5.84e-05	0.0014	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.78e-05	0.00138	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.76e-05	0.00138	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	5.74e-05	0.00138	CbGpPWpGaD
Ofloxacin—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	5.73e-05	0.00137	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—GSTO2—urinary bladder cancer	5.58e-05	0.00134	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—NAT1—urinary bladder cancer	5.58e-05	0.00134	CbGpPWpGaD
Ofloxacin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	5.53e-05	0.00133	CbGpPWpGaD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.5e-05	0.00132	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.48e-05	0.00131	CbGpPWpGaD
Ofloxacin—Sinusitis—Doxorubicin—urinary bladder cancer	5.43e-05	0.000299	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	5.43e-05	0.0013	CbGpPWpGaD
Ofloxacin—Immune system disorder—Methotrexate—urinary bladder cancer	5.42e-05	0.000298	CcSEcCtD
Ofloxacin—Dizziness—Fluorouracil—urinary bladder cancer	5.42e-05	0.000298	CcSEcCtD
Ofloxacin—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	5.42e-05	0.0013	CbGpPWpGaD
Ofloxacin—Visual impairment—Epirubicin—urinary bladder cancer	5.42e-05	0.000298	CcSEcCtD
Ofloxacin—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.41e-05	0.000297	CcSEcCtD
Ofloxacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.41e-05	0.000297	CcSEcCtD
Ofloxacin—Chills—Methotrexate—urinary bladder cancer	5.39e-05	0.000296	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.34e-05	0.00128	CbGpPWpGaD
Ofloxacin—Diarrhoea—Cisplatin—urinary bladder cancer	5.32e-05	0.000292	CcSEcCtD
Ofloxacin—Erythema multiforme—Epirubicin—urinary bladder cancer	5.31e-05	0.000292	CcSEcCtD
Ofloxacin—Alopecia—Methotrexate—urinary bladder cancer	5.31e-05	0.000292	CcSEcCtD
Ofloxacin—Vomiting—Gemcitabine—urinary bladder cancer	5.3e-05	0.000291	CcSEcCtD
Ofloxacin—Bradycardia—Doxorubicin—urinary bladder cancer	5.29e-05	0.000291	CcSEcCtD
Ofloxacin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	5.28e-05	0.00126	CbGpPWpGaD
Ofloxacin—Mental disorder—Methotrexate—urinary bladder cancer	5.26e-05	0.000289	CcSEcCtD
Ofloxacin—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	5.26e-05	0.00126	CbGpPWpGaD
Ofloxacin—Rash—Gemcitabine—urinary bladder cancer	5.26e-05	0.000289	CcSEcCtD
Ofloxacin—Dermatitis—Gemcitabine—urinary bladder cancer	5.26e-05	0.000289	CcSEcCtD
Ofloxacin—Eye disorder—Epirubicin—urinary bladder cancer	5.25e-05	0.000289	CcSEcCtD
Ofloxacin—Hypersensitivity—Etoposide—urinary bladder cancer	5.25e-05	0.000288	CcSEcCtD
Ofloxacin—Tinnitus—Epirubicin—urinary bladder cancer	5.24e-05	0.000288	CcSEcCtD
Ofloxacin—Malnutrition—Methotrexate—urinary bladder cancer	5.23e-05	0.000287	CcSEcCtD
Ofloxacin—Erythema—Methotrexate—urinary bladder cancer	5.23e-05	0.000287	CcSEcCtD
Ofloxacin—Haemoglobin—Doxorubicin—urinary bladder cancer	5.23e-05	0.000287	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	5.23e-05	0.00125	CbGpPWpGaD
Ofloxacin—Headache—Gemcitabine—urinary bladder cancer	5.23e-05	0.000287	CcSEcCtD
Ofloxacin—Cardiac disorder—Epirubicin—urinary bladder cancer	5.22e-05	0.000287	CcSEcCtD
Ofloxacin—Flushing—Epirubicin—urinary bladder cancer	5.22e-05	0.000287	CcSEcCtD
Ofloxacin—Vomiting—Fluorouracil—urinary bladder cancer	5.22e-05	0.000286	CcSEcCtD
Ofloxacin—Rhinitis—Doxorubicin—urinary bladder cancer	5.21e-05	0.000286	CcSEcCtD
Ofloxacin—Haemorrhage—Doxorubicin—urinary bladder cancer	5.2e-05	0.000286	CcSEcCtD
Ofloxacin—Hepatitis—Doxorubicin—urinary bladder cancer	5.2e-05	0.000286	CcSEcCtD
Ofloxacin—ABCC1—Disease—SLC19A1—urinary bladder cancer	5.18e-05	0.00124	CbGpPWpGaD
Ofloxacin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	5.17e-05	0.000284	CcSEcCtD
Ofloxacin—Rash—Fluorouracil—urinary bladder cancer	5.17e-05	0.000284	CcSEcCtD
Ofloxacin—Dermatitis—Fluorouracil—urinary bladder cancer	5.17e-05	0.000284	CcSEcCtD
Ofloxacin—Pharyngitis—Doxorubicin—urinary bladder cancer	5.16e-05	0.000284	CcSEcCtD
Ofloxacin—Headache—Fluorouracil—urinary bladder cancer	5.14e-05	0.000282	CcSEcCtD
Ofloxacin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.14e-05	0.000282	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	5.13e-05	0.00123	CbGpPWpGaD
Ofloxacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.12e-05	0.000281	CcSEcCtD
Ofloxacin—Dysgeusia—Methotrexate—urinary bladder cancer	5.12e-05	0.000281	CcSEcCtD
Ofloxacin—Asthenia—Etoposide—urinary bladder cancer	5.11e-05	0.000281	CcSEcCtD
Ofloxacin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.11e-05	0.000281	CcSEcCtD
Ofloxacin—Angiopathy—Epirubicin—urinary bladder cancer	5.1e-05	0.00028	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	5.1e-05	0.00122	CbGpPWpGaD
Ofloxacin—Urethral disorder—Doxorubicin—urinary bladder cancer	5.1e-05	0.00028	CcSEcCtD
Ofloxacin—Immune system disorder—Epirubicin—urinary bladder cancer	5.08e-05	0.000279	CcSEcCtD
Ofloxacin—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	5.08e-05	0.00122	CbGpPWpGaD
Ofloxacin—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.07e-05	0.000278	CcSEcCtD
Ofloxacin—Back pain—Methotrexate—urinary bladder cancer	5.06e-05	0.000278	CcSEcCtD
Ofloxacin—ABCC1—Disease—PRSS3—urinary bladder cancer	5.05e-05	0.00121	CbGpPWpGaD
Ofloxacin—Chills—Epirubicin—urinary bladder cancer	5.04e-05	0.000277	CcSEcCtD
Ofloxacin—Pruritus—Etoposide—urinary bladder cancer	5.04e-05	0.000277	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	5.03e-05	0.00121	CbGpPWpGaD
Ofloxacin—Arrhythmia—Epirubicin—urinary bladder cancer	5.02e-05	0.000276	CcSEcCtD
Ofloxacin—Visual impairment—Doxorubicin—urinary bladder cancer	5.01e-05	0.000275	CcSEcCtD
Ofloxacin—Alopecia—Epirubicin—urinary bladder cancer	4.97e-05	0.000273	CcSEcCtD
Ofloxacin—Nausea—Gemcitabine—urinary bladder cancer	4.96e-05	0.000272	CcSEcCtD
Ofloxacin—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.95e-05	0.00119	CbGpPWpGaD
Ofloxacin—Vomiting—Cisplatin—urinary bladder cancer	4.94e-05	0.000272	CcSEcCtD
Ofloxacin—Vision blurred—Methotrexate—urinary bladder cancer	4.93e-05	0.000271	CcSEcCtD
Ofloxacin—Mental disorder—Epirubicin—urinary bladder cancer	4.92e-05	0.00027	CcSEcCtD
Ofloxacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.92e-05	0.00027	CcSEcCtD
Ofloxacin—Rash—Cisplatin—urinary bladder cancer	4.9e-05	0.000269	CcSEcCtD
Ofloxacin—Dermatitis—Cisplatin—urinary bladder cancer	4.9e-05	0.000269	CcSEcCtD
Ofloxacin—Erythema—Epirubicin—urinary bladder cancer	4.89e-05	0.000269	CcSEcCtD
Ofloxacin—Malnutrition—Epirubicin—urinary bladder cancer	4.89e-05	0.000269	CcSEcCtD
Ofloxacin—Diarrhoea—Etoposide—urinary bladder cancer	4.87e-05	0.000268	CcSEcCtD
Ofloxacin—Nausea—Fluorouracil—urinary bladder cancer	4.87e-05	0.000268	CcSEcCtD
Ofloxacin—Eye disorder—Doxorubicin—urinary bladder cancer	4.86e-05	0.000267	CcSEcCtD
Ofloxacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.85e-05	0.000266	CcSEcCtD
Ofloxacin—Tinnitus—Doxorubicin—urinary bladder cancer	4.85e-05	0.000266	CcSEcCtD
Ofloxacin—Anaemia—Methotrexate—urinary bladder cancer	4.83e-05	0.000265	CcSEcCtD
Ofloxacin—Flushing—Doxorubicin—urinary bladder cancer	4.83e-05	0.000265	CcSEcCtD
Ofloxacin—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.83e-05	0.000265	CcSEcCtD
Ofloxacin—Flatulence—Epirubicin—urinary bladder cancer	4.82e-05	0.000265	CcSEcCtD
Ofloxacin—ABCC1—Disease—HDAC4—urinary bladder cancer	4.81e-05	0.00115	CbGpPWpGaD
Ofloxacin—Tension—Epirubicin—urinary bladder cancer	4.8e-05	0.000264	CcSEcCtD
Ofloxacin—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.79e-05	0.00115	CbGpPWpGaD
Ofloxacin—Dysgeusia—Epirubicin—urinary bladder cancer	4.79e-05	0.000263	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.79e-05	0.00115	CbGpPWpGaD
Ofloxacin—Nervousness—Epirubicin—urinary bladder cancer	4.75e-05	0.000261	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	4.74e-05	0.00114	CbGpPWpGaD
Ofloxacin—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.74e-05	0.00114	CbGpPWpGaD
Ofloxacin—Back pain—Epirubicin—urinary bladder cancer	4.73e-05	0.00026	CcSEcCtD
Ofloxacin—Angiopathy—Doxorubicin—urinary bladder cancer	4.72e-05	0.000259	CcSEcCtD
Ofloxacin—Malaise—Methotrexate—urinary bladder cancer	4.71e-05	0.000259	CcSEcCtD
Ofloxacin—Dizziness—Etoposide—urinary bladder cancer	4.71e-05	0.000259	CcSEcCtD
Ofloxacin—Muscle spasms—Epirubicin—urinary bladder cancer	4.7e-05	0.000258	CcSEcCtD
Ofloxacin—Immune system disorder—Doxorubicin—urinary bladder cancer	4.7e-05	0.000258	CcSEcCtD
Ofloxacin—Vertigo—Methotrexate—urinary bladder cancer	4.7e-05	0.000258	CcSEcCtD
Ofloxacin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.69e-05	0.000257	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.68e-05	0.00112	CbGpPWpGaD
Ofloxacin—Leukopenia—Methotrexate—urinary bladder cancer	4.68e-05	0.000257	CcSEcCtD
Ofloxacin—Chills—Doxorubicin—urinary bladder cancer	4.67e-05	0.000256	CcSEcCtD
Ofloxacin—Arrhythmia—Doxorubicin—urinary bladder cancer	4.65e-05	0.000255	CcSEcCtD
Ofloxacin—Nausea—Cisplatin—urinary bladder cancer	4.62e-05	0.000254	CcSEcCtD
Ofloxacin—Vision blurred—Epirubicin—urinary bladder cancer	4.61e-05	0.000253	CcSEcCtD
Ofloxacin—Alopecia—Doxorubicin—urinary bladder cancer	4.6e-05	0.000252	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	4.59e-05	0.0011	CbGpPWpGaD
Ofloxacin—Cough—Methotrexate—urinary bladder cancer	4.56e-05	0.000251	CcSEcCtD
Ofloxacin—Mental disorder—Doxorubicin—urinary bladder cancer	4.56e-05	0.00025	CcSEcCtD
Ofloxacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.54e-05	0.000249	CcSEcCtD
Ofloxacin—Vomiting—Etoposide—urinary bladder cancer	4.53e-05	0.000249	CcSEcCtD
Ofloxacin—Malnutrition—Doxorubicin—urinary bladder cancer	4.53e-05	0.000249	CcSEcCtD
Ofloxacin—Erythema—Doxorubicin—urinary bladder cancer	4.53e-05	0.000249	CcSEcCtD
Ofloxacin—Anaemia—Epirubicin—urinary bladder cancer	4.52e-05	0.000248	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	4.51e-05	0.00108	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	4.51e-05	0.00108	CbGpPWpGaD
Ofloxacin—Agitation—Epirubicin—urinary bladder cancer	4.5e-05	0.000247	CcSEcCtD
Ofloxacin—Rash—Etoposide—urinary bladder cancer	4.49e-05	0.000247	CcSEcCtD
Ofloxacin—Dermatitis—Etoposide—urinary bladder cancer	4.49e-05	0.000247	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	4.48e-05	0.00107	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	4.47e-05	0.00107	CbGpPWpGaD
Ofloxacin—Headache—Etoposide—urinary bladder cancer	4.46e-05	0.000245	CcSEcCtD
Ofloxacin—Flatulence—Doxorubicin—urinary bladder cancer	4.46e-05	0.000245	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.46e-05	0.00107	CbGpPWpGaD
Ofloxacin—Myalgia—Methotrexate—urinary bladder cancer	4.45e-05	0.000245	CcSEcCtD
Ofloxacin—Chest pain—Methotrexate—urinary bladder cancer	4.45e-05	0.000245	CcSEcCtD
Ofloxacin—Arthralgia—Methotrexate—urinary bladder cancer	4.45e-05	0.000245	CcSEcCtD
Ofloxacin—Tension—Doxorubicin—urinary bladder cancer	4.44e-05	0.000244	CcSEcCtD
Ofloxacin—Dysgeusia—Doxorubicin—urinary bladder cancer	4.43e-05	0.000244	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.42e-05	0.00106	CbGpPWpGaD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.42e-05	0.000243	CcSEcCtD
Ofloxacin—Malaise—Epirubicin—urinary bladder cancer	4.41e-05	0.000242	CcSEcCtD
Ofloxacin—Discomfort—Methotrexate—urinary bladder cancer	4.4e-05	0.000242	CcSEcCtD
Ofloxacin—Nervousness—Doxorubicin—urinary bladder cancer	4.4e-05	0.000242	CcSEcCtD
Ofloxacin—Vertigo—Epirubicin—urinary bladder cancer	4.4e-05	0.000241	CcSEcCtD
Ofloxacin—Syncope—Epirubicin—urinary bladder cancer	4.39e-05	0.000241	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	4.39e-05	0.00105	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	4.39e-05	0.00105	CbGpPWpGaD
Ofloxacin—Leukopenia—Epirubicin—urinary bladder cancer	4.38e-05	0.000241	CcSEcCtD
Ofloxacin—Back pain—Doxorubicin—urinary bladder cancer	4.38e-05	0.000241	CcSEcCtD
Ofloxacin—Muscle spasms—Doxorubicin—urinary bladder cancer	4.35e-05	0.000239	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	4.34e-05	0.00104	CbGpPWpGaD
Ofloxacin—Palpitations—Epirubicin—urinary bladder cancer	4.32e-05	0.000238	CcSEcCtD
Ofloxacin—Confusional state—Methotrexate—urinary bladder cancer	4.3e-05	0.000236	CcSEcCtD
Ofloxacin—Loss of consciousness—Epirubicin—urinary bladder cancer	4.3e-05	0.000236	CcSEcCtD
Ofloxacin—Cough—Epirubicin—urinary bladder cancer	4.27e-05	0.000235	CcSEcCtD
Ofloxacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.27e-05	0.000234	CcSEcCtD
Ofloxacin—Vision blurred—Doxorubicin—urinary bladder cancer	4.27e-05	0.000234	CcSEcCtD
Ofloxacin—Infection—Methotrexate—urinary bladder cancer	4.24e-05	0.000233	CcSEcCtD
Ofloxacin—Nausea—Etoposide—urinary bladder cancer	4.23e-05	0.000232	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—PRSS3—urinary bladder cancer	4.23e-05	0.00101	CbGpPWpGaD
Ofloxacin—Hypertension—Epirubicin—urinary bladder cancer	4.22e-05	0.000232	CcSEcCtD
Ofloxacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.2e-05	0.000231	CcSEcCtD
Ofloxacin—Nervous system disorder—Methotrexate—urinary bladder cancer	4.18e-05	0.00023	CcSEcCtD
Ofloxacin—Anaemia—Doxorubicin—urinary bladder cancer	4.18e-05	0.00023	CcSEcCtD
Ofloxacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.18e-05	0.000229	CcSEcCtD
Ofloxacin—Myalgia—Epirubicin—urinary bladder cancer	4.17e-05	0.000229	CcSEcCtD
Ofloxacin—Chest pain—Epirubicin—urinary bladder cancer	4.17e-05	0.000229	CcSEcCtD
Ofloxacin—Arthralgia—Epirubicin—urinary bladder cancer	4.17e-05	0.000229	CcSEcCtD
Ofloxacin—Agitation—Doxorubicin—urinary bladder cancer	4.16e-05	0.000229	CcSEcCtD
Ofloxacin—Anxiety—Epirubicin—urinary bladder cancer	4.15e-05	0.000228	CcSEcCtD
Ofloxacin—Skin disorder—Methotrexate—urinary bladder cancer	4.14e-05	0.000228	CcSEcCtD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.14e-05	0.000227	CcSEcCtD
Ofloxacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.12e-05	0.000227	CcSEcCtD
Ofloxacin—Discomfort—Epirubicin—urinary bladder cancer	4.12e-05	0.000226	CcSEcCtD
Ofloxacin—SLC22A4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.08e-05	0.000979	CbGpPWpGaD
Ofloxacin—Malaise—Doxorubicin—urinary bladder cancer	4.08e-05	0.000224	CcSEcCtD
Ofloxacin—Dry mouth—Epirubicin—urinary bladder cancer	4.07e-05	0.000224	CcSEcCtD
Ofloxacin—Vertigo—Doxorubicin—urinary bladder cancer	4.07e-05	0.000223	CcSEcCtD
Ofloxacin—Anorexia—Methotrexate—urinary bladder cancer	4.07e-05	0.000223	CcSEcCtD
Ofloxacin—Syncope—Doxorubicin—urinary bladder cancer	4.06e-05	0.000223	CcSEcCtD
Ofloxacin—Leukopenia—Doxorubicin—urinary bladder cancer	4.05e-05	0.000223	CcSEcCtD
Ofloxacin—Confusional state—Epirubicin—urinary bladder cancer	4.03e-05	0.000221	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	4.02e-05	0.000963	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	4e-05	0.000959	CbGpPWpGaD
Ofloxacin—Palpitations—Doxorubicin—urinary bladder cancer	4e-05	0.00022	CcSEcCtD
Ofloxacin—Oedema—Epirubicin—urinary bladder cancer	3.99e-05	0.000219	CcSEcCtD
Ofloxacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.99e-05	0.000219	CcSEcCtD
Ofloxacin—Hypotension—Methotrexate—urinary bladder cancer	3.99e-05	0.000219	CcSEcCtD
Ofloxacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.98e-05	0.000219	CcSEcCtD
Ofloxacin—Infection—Epirubicin—urinary bladder cancer	3.97e-05	0.000218	CcSEcCtD
Ofloxacin—Cough—Doxorubicin—urinary bladder cancer	3.95e-05	0.000217	CcSEcCtD
Ofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.93e-05	0.000943	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	3.93e-05	0.000943	CbGpPWpGaD
Ofloxacin—Shock—Epirubicin—urinary bladder cancer	3.93e-05	0.000216	CcSEcCtD
Ofloxacin—Nervous system disorder—Epirubicin—urinary bladder cancer	3.92e-05	0.000215	CcSEcCtD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.92e-05	0.000939	CbGpPWpGaD
Ofloxacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.91e-05	0.000215	CcSEcCtD
Ofloxacin—Hypertension—Doxorubicin—urinary bladder cancer	3.91e-05	0.000215	CcSEcCtD
Ofloxacin—Tachycardia—Epirubicin—urinary bladder cancer	3.9e-05	0.000214	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	3.89e-05	0.000933	CbGpPWpGaD
Ofloxacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.89e-05	0.000214	CcSEcCtD
Ofloxacin—Skin disorder—Epirubicin—urinary bladder cancer	3.88e-05	0.000213	CcSEcCtD
Ofloxacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.86e-05	0.000212	CcSEcCtD
Ofloxacin—Insomnia—Methotrexate—urinary bladder cancer	3.86e-05	0.000212	CcSEcCtD
Ofloxacin—Chest pain—Doxorubicin—urinary bladder cancer	3.85e-05	0.000212	CcSEcCtD
Ofloxacin—Arthralgia—Doxorubicin—urinary bladder cancer	3.85e-05	0.000212	CcSEcCtD
Ofloxacin—Myalgia—Doxorubicin—urinary bladder cancer	3.85e-05	0.000212	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	3.85e-05	0.000922	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	3.85e-05	0.000922	CbGpPWpGaD
Ofloxacin—Anxiety—Doxorubicin—urinary bladder cancer	3.84e-05	0.000211	CcSEcCtD
Ofloxacin—Paraesthesia—Methotrexate—urinary bladder cancer	3.83e-05	0.00021	CcSEcCtD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.83e-05	0.00021	CcSEcCtD
Ofloxacin—ABCC1—Disease—LIG1—urinary bladder cancer	3.82e-05	0.000917	CbGpPWpGaD
Ofloxacin—Discomfort—Doxorubicin—urinary bladder cancer	3.81e-05	0.000209	CcSEcCtD
Ofloxacin—Anorexia—Epirubicin—urinary bladder cancer	3.81e-05	0.000209	CcSEcCtD
Ofloxacin—Dyspnoea—Methotrexate—urinary bladder cancer	3.8e-05	0.000209	CcSEcCtD
Ofloxacin—Somnolence—Methotrexate—urinary bladder cancer	3.79e-05	0.000208	CcSEcCtD
Ofloxacin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	3.78e-05	0.000905	CbGpPWpGaD
Ofloxacin—Dry mouth—Doxorubicin—urinary bladder cancer	3.77e-05	0.000207	CcSEcCtD
Ofloxacin—Dyspepsia—Methotrexate—urinary bladder cancer	3.76e-05	0.000206	CcSEcCtD
Ofloxacin—Hypotension—Epirubicin—urinary bladder cancer	3.73e-05	0.000205	CcSEcCtD
Ofloxacin—Confusional state—Doxorubicin—urinary bladder cancer	3.73e-05	0.000205	CcSEcCtD
Ofloxacin—Decreased appetite—Methotrexate—urinary bladder cancer	3.71e-05	0.000204	CcSEcCtD
Ofloxacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.69e-05	0.000203	CcSEcCtD
Ofloxacin—Oedema—Doxorubicin—urinary bladder cancer	3.69e-05	0.000203	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.68e-05	0.000202	CcSEcCtD
Ofloxacin—Fatigue—Methotrexate—urinary bladder cancer	3.68e-05	0.000202	CcSEcCtD
Ofloxacin—Infection—Doxorubicin—urinary bladder cancer	3.67e-05	0.000202	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	3.66e-05	0.000878	CbGpPWpGaD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.66e-05	0.000878	CbGpPWpGaD
Ofloxacin—Pain—Methotrexate—urinary bladder cancer	3.65e-05	0.0002	CcSEcCtD
Ofloxacin—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	3.65e-05	0.000874	CbGpPWpGaD
Ofloxacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.64e-05	0.0002	CcSEcCtD
Ofloxacin—Shock—Doxorubicin—urinary bladder cancer	3.64e-05	0.0002	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.63e-05	0.000871	CbGpPWpGaD
Ofloxacin—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.62e-05	0.000199	CcSEcCtD
Ofloxacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.62e-05	0.000199	CcSEcCtD
Ofloxacin—Insomnia—Epirubicin—urinary bladder cancer	3.61e-05	0.000198	CcSEcCtD
Ofloxacin—Tachycardia—Doxorubicin—urinary bladder cancer	3.61e-05	0.000198	CcSEcCtD
Ofloxacin—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.6e-05	0.000862	CbGpPWpGaD
Ofloxacin—Skin disorder—Doxorubicin—urinary bladder cancer	3.59e-05	0.000197	CcSEcCtD
Ofloxacin—Paraesthesia—Epirubicin—urinary bladder cancer	3.59e-05	0.000197	CcSEcCtD
Ofloxacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.57e-05	0.000196	CcSEcCtD
Ofloxacin—Dyspnoea—Epirubicin—urinary bladder cancer	3.56e-05	0.000196	CcSEcCtD
Ofloxacin—Somnolence—Epirubicin—urinary bladder cancer	3.55e-05	0.000195	CcSEcCtD
Ofloxacin—Anorexia—Doxorubicin—urinary bladder cancer	3.52e-05	0.000193	CcSEcCtD
Ofloxacin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.52e-05	0.000193	CcSEcCtD
Ofloxacin—Dyspepsia—Epirubicin—urinary bladder cancer	3.51e-05	0.000193	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.49e-05	0.000192	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	3.48e-05	0.000834	CbGpPWpGaD
Ofloxacin—Decreased appetite—Epirubicin—urinary bladder cancer	3.47e-05	0.000191	CcSEcCtD
Ofloxacin—Hypotension—Doxorubicin—urinary bladder cancer	3.45e-05	0.00019	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.45e-05	0.000189	CcSEcCtD
Ofloxacin—Fatigue—Epirubicin—urinary bladder cancer	3.44e-05	0.000189	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	3.42e-05	0.00082	CbGpPWpGaD
Ofloxacin—Pain—Epirubicin—urinary bladder cancer	3.41e-05	0.000188	CcSEcCtD
Ofloxacin—Constipation—Epirubicin—urinary bladder cancer	3.41e-05	0.000188	CcSEcCtD
Ofloxacin—Urticaria—Methotrexate—urinary bladder cancer	3.39e-05	0.000186	CcSEcCtD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.39e-05	0.000812	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—TYMP—urinary bladder cancer	3.38e-05	0.00081	CbGpPWpGaD
Ofloxacin—Abdominal pain—Methotrexate—urinary bladder cancer	3.37e-05	0.000185	CcSEcCtD
Ofloxacin—Body temperature increased—Methotrexate—urinary bladder cancer	3.37e-05	0.000185	CcSEcCtD
Ofloxacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.37e-05	0.000185	CcSEcCtD
Ofloxacin—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	3.35e-05	0.000803	CbGpPWpGaD
Ofloxacin—Insomnia—Doxorubicin—urinary bladder cancer	3.34e-05	0.000184	CcSEcCtD
Ofloxacin—Paraesthesia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000182	CcSEcCtD
Ofloxacin—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.3e-05	0.000792	CbGpPWpGaD
Ofloxacin—Dyspnoea—Doxorubicin—urinary bladder cancer	3.29e-05	0.000181	CcSEcCtD
Ofloxacin—Feeling abnormal—Epirubicin—urinary bladder cancer	3.29e-05	0.000181	CcSEcCtD
Ofloxacin—Somnolence—Doxorubicin—urinary bladder cancer	3.28e-05	0.00018	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.27e-05	0.000179	CcSEcCtD
Ofloxacin—Dyspepsia—Doxorubicin—urinary bladder cancer	3.25e-05	0.000179	CcSEcCtD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.24e-05	0.000778	CbGpPWpGaD
Ofloxacin—Decreased appetite—Doxorubicin—urinary bladder cancer	3.21e-05	0.000176	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.19e-05	0.000175	CcSEcCtD
Ofloxacin—Fatigue—Doxorubicin—urinary bladder cancer	3.19e-05	0.000175	CcSEcCtD
Ofloxacin—Urticaria—Epirubicin—urinary bladder cancer	3.17e-05	0.000174	CcSEcCtD
Ofloxacin—Pain—Doxorubicin—urinary bladder cancer	3.16e-05	0.000174	CcSEcCtD
Ofloxacin—Constipation—Doxorubicin—urinary bladder cancer	3.16e-05	0.000174	CcSEcCtD
Ofloxacin—Body temperature increased—Epirubicin—urinary bladder cancer	3.16e-05	0.000173	CcSEcCtD
Ofloxacin—Abdominal pain—Epirubicin—urinary bladder cancer	3.16e-05	0.000173	CcSEcCtD
Ofloxacin—Hypersensitivity—Methotrexate—urinary bladder cancer	3.14e-05	0.000173	CcSEcCtD
Ofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	3.09e-05	0.00074	CbGpPWpGaD
Ofloxacin—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.07e-05	0.000736	CbGpPWpGaD
Ofloxacin—Asthenia—Methotrexate—urinary bladder cancer	3.06e-05	0.000168	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	3.06e-05	0.000733	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—NAT2—urinary bladder cancer	3.05e-05	0.000732	CbGpPWpGaD
Ofloxacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.04e-05	0.000167	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.02e-05	0.000166	CcSEcCtD
Ofloxacin—Pruritus—Methotrexate—urinary bladder cancer	3.02e-05	0.000166	CcSEcCtD
Ofloxacin—Hypersensitivity—Epirubicin—urinary bladder cancer	2.94e-05	0.000162	CcSEcCtD
Ofloxacin—Urticaria—Doxorubicin—urinary bladder cancer	2.94e-05	0.000161	CcSEcCtD
Ofloxacin—Abdominal pain—Doxorubicin—urinary bladder cancer	2.92e-05	0.00016	CcSEcCtD
Ofloxacin—Body temperature increased—Doxorubicin—urinary bladder cancer	2.92e-05	0.00016	CcSEcCtD
Ofloxacin—Diarrhoea—Methotrexate—urinary bladder cancer	2.92e-05	0.00016	CcSEcCtD
Ofloxacin—ABCC1—Disease—ENO2—urinary bladder cancer	2.92e-05	0.000699	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	2.89e-05	0.000693	CbGpPWpGaD
Ofloxacin—Asthenia—Epirubicin—urinary bladder cancer	2.86e-05	0.000157	CcSEcCtD
Ofloxacin—Pruritus—Epirubicin—urinary bladder cancer	2.83e-05	0.000155	CcSEcCtD
Ofloxacin—Dizziness—Methotrexate—urinary bladder cancer	2.82e-05	0.000155	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	2.8e-05	0.00067	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—RBX1—urinary bladder cancer	2.76e-05	0.000663	CbGpPWpGaD
Ofloxacin—Diarrhoea—Epirubicin—urinary bladder cancer	2.73e-05	0.00015	CcSEcCtD
Ofloxacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.72e-05	0.00015	CcSEcCtD
Ofloxacin—Vomiting—Methotrexate—urinary bladder cancer	2.71e-05	0.000149	CcSEcCtD
Ofloxacin—Rash—Methotrexate—urinary bladder cancer	2.69e-05	0.000148	CcSEcCtD
Ofloxacin—Dermatitis—Methotrexate—urinary bladder cancer	2.69e-05	0.000148	CcSEcCtD
Ofloxacin—Headache—Methotrexate—urinary bladder cancer	2.67e-05	0.000147	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	2.66e-05	0.000638	CbGpPWpGaD
Ofloxacin—Asthenia—Doxorubicin—urinary bladder cancer	2.65e-05	0.000146	CcSEcCtD
Ofloxacin—Dizziness—Epirubicin—urinary bladder cancer	2.64e-05	0.000145	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—RRM2—urinary bladder cancer	2.64e-05	0.000632	CbGpPWpGaD
Ofloxacin—Pruritus—Doxorubicin—urinary bladder cancer	2.61e-05	0.000144	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	2.58e-05	0.00062	CbGpPWpGaD
Ofloxacin—Vomiting—Epirubicin—urinary bladder cancer	2.54e-05	0.000139	CcSEcCtD
Ofloxacin—Nausea—Methotrexate—urinary bladder cancer	2.53e-05	0.000139	CcSEcCtD
Ofloxacin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.53e-05	0.000139	CcSEcCtD
Ofloxacin—Rash—Epirubicin—urinary bladder cancer	2.52e-05	0.000138	CcSEcCtD
Ofloxacin—Dermatitis—Epirubicin—urinary bladder cancer	2.52e-05	0.000138	CcSEcCtD
Ofloxacin—Headache—Epirubicin—urinary bladder cancer	2.5e-05	0.000137	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	2.5e-05	0.000599	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—JAG1—urinary bladder cancer	2.47e-05	0.000593	CbGpPWpGaD
Ofloxacin—Dizziness—Doxorubicin—urinary bladder cancer	2.44e-05	0.000134	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—HPGDS—urinary bladder cancer	2.44e-05	0.000585	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—ENO2—urinary bladder cancer	2.44e-05	0.000585	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.43e-05	0.000582	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	2.38e-05	0.00057	CbGpPWpGaD
Ofloxacin—Nausea—Epirubicin—urinary bladder cancer	2.37e-05	0.00013	CcSEcCtD
Ofloxacin—ABCC1—Metabolism—GSTT1—urinary bladder cancer	2.37e-05	0.000568	CbGpPWpGaD
Ofloxacin—Vomiting—Doxorubicin—urinary bladder cancer	2.35e-05	0.000129	CcSEcCtD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.33e-05	0.000559	CbGpPWpGaD
Ofloxacin—Rash—Doxorubicin—urinary bladder cancer	2.33e-05	0.000128	CcSEcCtD
Ofloxacin—Dermatitis—Doxorubicin—urinary bladder cancer	2.33e-05	0.000128	CcSEcCtD
Ofloxacin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.32e-05	0.000556	CbGpPWpGaD
Ofloxacin—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.32e-05	0.000555	CbGpPWpGaD
Ofloxacin—Headache—Doxorubicin—urinary bladder cancer	2.31e-05	0.000127	CcSEcCtD
Ofloxacin—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.24e-05	0.000538	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.23e-05	0.000535	CbGpPWpGaD
Ofloxacin—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.22e-05	0.000532	CbGpPWpGaD
Ofloxacin—Nausea—Doxorubicin—urinary bladder cancer	2.19e-05	0.000121	CcSEcCtD
Ofloxacin—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2.12e-05	0.000508	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2.12e-05	0.000508	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.08e-05	0.000499	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.07e-05	0.000497	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—NQO1—urinary bladder cancer	1.97e-05	0.000472	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	1.94e-05	0.000464	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.91e-05	0.000458	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—NCOR1—urinary bladder cancer	1.8e-05	0.000432	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.74e-05	0.000418	CbGpPWpGaD
Ofloxacin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	1.7e-05	0.000408	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—ERCC2—urinary bladder cancer	1.69e-05	0.000406	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.67e-05	0.000399	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.65e-05	0.000395	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—GSTP1—urinary bladder cancer	1.64e-05	0.000394	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.6e-05	0.000385	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—MTHFR—urinary bladder cancer	1.59e-05	0.000382	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.59e-05	0.000381	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—TERT—urinary bladder cancer	1.59e-05	0.000381	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—TYMS—urinary bladder cancer	1.53e-05	0.000366	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—GSTM1—urinary bladder cancer	1.51e-05	0.000362	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—NCOR1—urinary bladder cancer	1.51e-05	0.000362	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—FGFR3—urinary bladder cancer	1.46e-05	0.000349	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—GPX1—urinary bladder cancer	1.44e-05	0.000346	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	1.42e-05	0.00034	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.33e-05	0.00032	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.29e-05	0.000308	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.28e-05	0.000308	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—CREBBP—urinary bladder cancer	1.24e-05	0.000297	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.23e-05	0.000295	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.16e-05	0.000278	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—RHOA—urinary bladder cancer	1.12e-05	0.000269	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.08e-05	0.000259	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	0.000249	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—ERBB2—urinary bladder cancer	1.04e-05	0.000249	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—PTGS2—urinary bladder cancer	1.02e-05	0.000243	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1e-05	0.00024	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—ENO2—urinary bladder cancer	9.27e-06	0.000222	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	9.27e-06	0.000222	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.22e-06	0.000221	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	9e-06	0.000216	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—CDKN1A—urinary bladder cancer	8.88e-06	0.000213	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.86e-06	0.000212	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—PTEN—urinary bladder cancer	8.86e-06	0.000212	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	8.51e-06	0.000204	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—EP300—urinary bladder cancer	8.45e-06	0.000202	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—SRC—urinary bladder cancer	8.21e-06	0.000197	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—NQO1—urinary bladder cancer	7.48e-06	0.000179	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—PTEN—urinary bladder cancer	7.42e-06	0.000178	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—MYC—urinary bladder cancer	7.36e-06	0.000176	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.25e-06	0.000174	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—EGFR—urinary bladder cancer	7.2e-06	0.000173	CbGpPWpGaD
Ofloxacin—ABCC1—Metabolism—EP300—urinary bladder cancer	7.07e-06	0.00017	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—KRAS—urinary bladder cancer	6.8e-06	0.000163	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.33e-06	0.000152	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	6.24e-06	0.000149	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.03e-06	0.000145	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	5.8e-06	0.000139	CbGpPWpGaD
Ofloxacin—ABCC1—Disease—HRAS—urinary bladder cancer	5.78e-06	0.000139	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	5.73e-06	0.000137	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	5.73e-06	0.000137	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.49e-06	0.000132	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.39e-06	0.000129	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	5.06e-06	0.000121	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.11e-06	9.84e-05	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	3.94e-06	9.46e-05	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.23e-06	7.74e-05	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.82e-06	6.75e-05	CbGpPWpGaD
Ofloxacin—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.69e-06	6.44e-05	CbGpPWpGaD
